GOLDBERG; MICHAEL E.

Patent Applications and Registrations

Patent applications and USPTO patent grants for GOLDBERG; MICHAEL E..The latest application filed is for "use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)-ketamine in the treatment of depression and neuropathic pain".

Company Profile

0.6.9

GOLDBERG; MICHAEL E. - Philadelphia PA
Goldberg; Michael E. - Ivyland PA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)-ketamine In The Treatment Of Depression And Neuropathic Pain App 20200360393 - WAINER; IRVING W. ; et al.	2020-11-19
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20180098993 - WAINER; IRVING W. ; et al.	2018-04-12
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain Grant 9,867,830 - Wainer , et al. January 16, 2	2018-01-16
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain Grant 9,650,352 - Wainer , et al. May 16, 2	2017-05-16
Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20170049780 - WAINER; IRVING W. ; et al.	2017-02-23
The Use Of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine And Other Stereoisomeric Dehydro And Hydroxylated Metabolites Of (r,s)- Ketamine In The Treatment Of Depression And Neuropathic Pain App 20140296241 - Wainer; Irving W. ; et al.	2014-10-02
Wearable Automated Blood Sampling and Monitoring System App 20090264720 - Torjman; Marc C. ; et al.	2009-10-22
Compositions and methods for improving recovery after general anesthesia Grant 7,528,172 - Larijani , et al. May 5, 2	2009-05-05
Dutasteride to prevent and treat atherosclerosis Grant 6,630,164 - Weisman , et al. October 7, 2	2003-10-07
Use of saw palmetto to prevent atherosclerosis Grant 6,627,227 - Weisman , et al. September 30, 2	2003-09-30
Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis Grant 6,479,063 - Weisman , et al. November 12, 2	2002-11-12
Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis App 20020006399 - Weisman, Kenneth ; et al.	2002-01-17
Use of HMG-COA reductase inhibitors to prevent and treat BPH App 20020004521 - Weisman, Kenneth ; et al.	2002-01-10
Use of saw palmetto to prevent atherosclerosis App 20010053391 - Weisman, Kenneth ; et al.	2001-12-20
Dutasteride to prevent and treat atherosclerosis App 20010048942 - Weisman, Kenneth ; et al.	2001-12-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.